BR112022011723A2 - Anticorpo anti-ctla-4 e uso do mesmo - Google Patents

Anticorpo anti-ctla-4 e uso do mesmo

Info

Publication number
BR112022011723A2
BR112022011723A2 BR112022011723A BR112022011723A BR112022011723A2 BR 112022011723 A2 BR112022011723 A2 BR 112022011723A2 BR 112022011723 A BR112022011723 A BR 112022011723A BR 112022011723 A BR112022011723 A BR 112022011723A BR 112022011723 A2 BR112022011723 A2 BR 112022011723A2
Authority
BR
Brazil
Prior art keywords
ctla
antibody
present
producing
nucleic acid
Prior art date
Application number
BR112022011723A
Other languages
English (en)
Other versions
BR112022011723B1 (pt
Inventor
Katada Hitoshi
Tatsumi Kanako
Matsuda Yutaka
shimizu Shun
KAMIMURA Masaki
Komori Yasunori
Hori Yuji
Igawa Tomoyuki
Kawauchi Hiroki
Susumu Hiroaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112022011723A2 publication Critical patent/BR112022011723A2/pt
Publication of BR112022011723B1 publication Critical patent/BR112022011723B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPO ANTI-CTLA-4 E USO DO MESMO. A presente invenção refere-se a um anticorpo anti-CTLA-4 e métodos para produção e uso do mesmo. A presente invenção ainda fornece: um ácido nucleico codificando o referido anticorpo anti-CTLA-4; e células hospedeiras incluindo o referido ácido nucleico. A presente invenção ainda refere-se a: um polipeptídeo incluindo uma região Fc variante; e métodos para produção e uso do referido polipeptídeo.
BR112022011723-0A 2019-12-27 Anticorpo anti-ctla-4, e formulação farmacêutica BR112022011723B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2019/051447 WO2021131021A1 (ja) 2019-12-27 2019-12-27 抗ｃｔｌａ－４抗体およびその使用

Publications (2)

Publication Number Publication Date
BR112022011723A2 true BR112022011723A2 (pt) 2022-09-06
BR112022011723B1 BR112022011723B1 (pt) 2024-09-24

Family

ID=

Also Published As

Publication number Publication date
CO2022010422A2 (es) 2022-09-09
CA3162444C (en) 2024-04-30
PE20221585A1 (es) 2022-10-06
WO2021131021A1 (ja) 2021-07-01
CN115942956A (zh) 2023-04-07
KR20220119433A (ko) 2022-08-29
AU2019479791A1 (en) 2022-07-14
AU2019479791B2 (en) 2024-05-02
US20230058982A1 (en) 2023-02-23
JPWO2021131021A1 (pt) 2021-07-01
MX2022007840A (es) 2022-07-19
EP4082570A4 (en) 2023-09-13
CA3162444A1 (en) 2021-07-01
UA128549C2 (uk) 2024-08-07
EP4082570A1 (en) 2022-11-02
JP7373588B2 (ja) 2023-11-02
KR102645629B1 (ko) 2024-03-07
KR20240035914A (ko) 2024-03-18
IL294226A (en) 2022-08-01
CR20220357A (es) 2022-08-24
JP2024010057A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018074325A2 (pt) anticorpo para ligação a receptor de interleucina 4
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018073628A2 (pt) anticorpos antimiostatina e métodos de utilização
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
UY37758A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112021021843A8 (pt) Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112019008702A2 (pt) polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201690299A1 (ru) СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
PE20151613A1 (es) Construcciones de anticuerpos para cdh19 y cd3
BR112017023131A2 (pt) anticorpos anti- fcrn
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
CO2022010422A2 (es) Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
BR112021016272A2 (pt) Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
AR118763A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
MX2020004512A (es) Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.
UY37752A (es) Proteínas de unión al antígeno anti-jagged1

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/12/2019, OBSERVADAS AS CONDICOES LEGAIS